昆药集团
(600422)
| 流通市值：122.78亿 | | | 总市值：122.78亿 |
| 流通股本：7.57亿 | | | 总股本：7.57亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 5,457,454,882.94 | 3,554,421,628.96 | 1,852,637,983.31 | 7,703,121,256.83 |
| 营业收入 | 5,457,454,882.94 | 3,554,421,628.96 | 1,852,637,983.31 | 7,703,121,256.83 |
| 二、营业总成本 | 5,001,893,407.76 | 3,302,177,686.87 | 1,681,940,225.73 | 7,153,005,232.63 |
| 营业成本 | 3,224,711,276.3 | 2,093,421,272.54 | 1,089,547,848.12 | 4,250,580,509.27 |
| 税金及附加 | 52,889,408.55 | 35,529,313.46 | 16,418,280.81 | 74,707,054.84 |
| 销售费用 | 1,418,514,480 | 976,057,518.5 | 476,962,083.94 | 2,432,640,868.01 |
| 管理费用 | 228,950,764.83 | 148,045,124.22 | 75,456,728.58 | 313,544,474.81 |
| 研发费用 | 60,014,539.23 | 38,137,405.53 | 17,215,457.38 | 71,263,309.76 |
| 财务费用 | 16,812,938.85 | 10,987,052.62 | 6,339,826.9 | 10,269,015.94 |
| 其中:利息费用 | 19,629,866.98 | 13,168,883.6 | 6,565,939.91 | 21,589,962.71 |
| 其中:利息收入 | 6,642,226.89 | 4,330,355.95 | 1,744,026.06 | 12,048,361.25 |
| 加:公允价值变动收益 | -176,072.35 | 2,082,746.44 | -321,823.57 | 1,026,092.86 |
| 加:投资收益 | 12,246,296.01 | 9,176,440 | 776,466.59 | 17,312,225.9 |
| 资产处置收益 | 261,494.05 | 363,894.7 | 267,965.77 | 978,266.91 |
| 资产减值损失(新) | -14,670,900.64 | -14,997,501.35 | -6,269,577.01 | -65,934,507.71 |
| 信用减值损失(新) | -52,062,124.86 | -37,167,086.68 | -25,586,938.09 | -52,858,543.98 |
| 其他收益 | 85,686,902.79 | 71,931,700.1 | 7,982,842.32 | 117,856,325.9 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 486,847,070.18 | 283,634,135.3 | 147,546,693.59 | 568,495,884.08 |
| 加:营业外收入 | 4,508,338.29 | 2,770,528.55 | 751,024.9 | 6,062,271.45 |
| 减:营业外支出 | -6,150,692.16 | 1,977,869.74 | 503,269.55 | 10,938,256.39 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 497,506,100.63 | 284,426,794.11 | 147,794,448.94 | 563,619,899.14 |
| 减:所得税费用 | 106,993,019.77 | 50,720,444.06 | 26,822,788.99 | 109,477,183.59 |
| 六、净利润 | 390,513,080.86 | 233,706,350.05 | 120,971,659.95 | 454,142,715.55 |
| 持续经营净利润 | 390,513,080.86 | 233,706,350.05 | 120,971,659.95 | 454,142,715.55 |
| 归属于母公司股东的净利润 | 387,395,872.22 | 229,483,348.45 | 118,693,454.55 | 444,679,961.22 |
| 少数股东损益 | 3,117,208.64 | 4,223,001.6 | 2,278,205.4 | 9,462,754.33 |
| (一)基本每股收益 | 0.51 | 0.3 | 0.16 | 0.59 |
| (二)稀释每股收益 | 0.51 | 0.3 | 0.16 | 0.59 |
| 八、其他综合收益 | -987,127.81 | -89,266 | -104,249.48 | -7,802,549.3 |
| 归属于母公司股东的其他综合收益 | -915,314.42 | -58,384.82 | -104,249.48 | -7,907,329.72 |
| 九、综合收益总额 | 389,525,953.05 | 233,617,084.05 | 120,867,410.47 | 446,340,166.25 |
| 归属于母公司股东的综合收益总额 | 386,480,557.8 | 229,424,963.63 | 118,589,205.07 | 436,772,631.5 |
| 归属于少数股东的综合收益总额 | 3,045,395.25 | 4,192,120.42 | 2,278,205.4 | 9,567,534.75 |
| 公告日期 | 2024-10-26 | 2024-08-23 | 2024-04-20 | 2024-03-22 |
| 审计意见(境内) | | | | 标准无保留意见 |